Clinical Trial

An Extension of SKY-0515 in Participants With Huntington's Disease

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Protocol Amendment History 2 changes
notable Trial sites expanded: 4 -> 10 locations 2026-07-24
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-04-25
Trial Details
NCT Number NCT07537075
Lead Sponsor Skyhawk Therapeutics, Inc.
Conditions Huntington's Disease (HD)
Enrollment 500 participants
Start Date 2026-04-10
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24